Immunovant shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential ...

The CALM-CAH Phase 3 study is a randomized, placebo-controlled trial evaluating atumelnant in adults with classic CAH, designed to assess reductions in excess androgens, improvements in glucocorticoid ...

Immunovant ( ($IMVT) ) has issued an announcement. On December 10, 2025, Immunovant announced the pricing of an underwritten offering of its ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...

"[Williams] does not have frontotemporal dementia, so that should be game, set, match," famed attorney Joe Tacopina said in ...

Watts challenged the decision in the Personal Injury Commission and represented himself during the proceedings. EML’s case ...

New Chronic Wasting Disease surveillance measures are now in effect for Casey, Laurel, Lincoln, McCreary, Pulaski, Rockcastle ...

The Kentucky Department of Fish and Wildlife has expanded chronic wasting disease surveillance measures to nine counties ...

Danish archaeologists unearthed dozens of medieval graves, shedding light on how disease and hardship shaped life in early ...

Here are four patient and professional organizations that provide information and support for people who are living with Graves’ disease.

On behalf of the American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and ...